Skip to main content
Nicox S.A. logo

Nicox S.A. — Investor Relations & Filings

Ticker · COX ISIN · FR0013018124 LEI · 969500EZGEO9W4JXR353 PA Professional, scientific and technical activities
Open in API
Filings indexed 799 across all filing types
Latest filing 2023-03-03 Investor Presentation
Country FR France
Listing PA COX

About Nicox S.A.

https://www.nicox.com/

Nicox S.A. is an international ophthalmology company focused on the research and development of innovative therapeutic solutions to maintain vision and improve ocular health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost analog in late-stage clinical development for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox's pipeline is based on its proprietary NO-donating research platform. The company has also developed two approved ophthalmic products: VYZULTA® (latanoprostene bunod ophthalmic solution), licensed exclusively to Bausch + Lomb, and ZERVIATE® (cetirizine ophthalmic solution), licensed to various partners for commercialization.

Recent filings

Filing Released Lang Actions
Nicox : Présentations à des conférences scientifiques
Investor Presentation Classification · 90% confidence The document is titled "Communiqué de presse" (Press Release) and announces that Nicox will be presenting data at two upcoming scientific conferences: the American Glaucoma Society (AGS) Annual Meeting and the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. It details the titles, dates, and presenters for specific poster and session presentations related to their drug candidates (NCX 470 and NCX 1728). This type of announcement, detailing participation in industry events and scientific presentations, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or a general announcement. Since this is a press release announcing future scientific presentations and providing context on their pipeline, it aligns best with providing information intended for investors about ongoing research and development activities, which falls under Investor Presentation (IP) or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the focus on scientific data dissemination and pipeline updates, IP is a strong candidate. However, because it is a general press release announcing participation in external scientific conferences rather than a formal company presentation or a mandatory financial filing, and it doesn't fit perfectly into the specific categories like ER, IR, or 10-K, it is best categorized as a general announcement. In the context of the provided definitions, it is an announcement about company activities, but not a formal report itself. Since it is a press release detailing scientific updates, it is most closely related to the information shared in an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the content is highly focused on R&D updates presented at scientific meetings, IP is the most specific fit among the options that cover non-financial performance updates. If it were purely a mandatory disclosure without the scientific presentation detail, RNS would be used. I will classify it as Investor Presentation (IP) as it details scientific findings being presented to the investment community via conferences.
2023-03-03 French
Nicox to Present at Upcoming Scientific Conferences
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Press Release" and announces that Nicox will be presenting scientific data at upcoming ophthalmology conferences (AGS 2023 and ARVO 2023). It details poster titles, session times, and presenters. This type of announcement, which communicates upcoming corporate activities (presentations, events) rather than releasing mandatory periodic financial results (like 10-K or IR) or official voting results, fits best under a general regulatory/corporate announcement category. Since it is not a specific financial report, management change, dividend notice, or proxy material, the most appropriate classification is Regulatory Filings (RNS), which serves as a general category for corporate announcements that don't fit elsewhere. The document length (6402 chars) is substantial enough that it is not merely a brief notification of a report being available (which would suggest RPA).
2023-03-03 English
Nombre de droits de vote au 28 février 2023
Share Issue/Capital Change Classification · 95% confidence The document is titled "PUBLICATION MENSUELLE DU NOMBRE D'ACTIONS COMPOSANT LE CAPITAL ET DU NOMBRE TOTAL DE DROITS DE VOTE" (Monthly publication of the number of shares comprising the capital and the total number of voting rights). It explicitly references French regulatory articles (Code de Commerce and AMF regulations) and provides a snapshot of the share capital and voting rights as of February 28, 2023. This type of regular, mandatory disclosure regarding share structure and voting power does not fit neatly into the primary financial report categories (10-K, IR, ER). It is a specific regulatory disclosure. Since there is no dedicated code for 'Monthly Share Capital Disclosure', the most appropriate fallback category is 'Regulatory Filings' (RNS), as it represents a mandatory, periodic regulatory announcement that isn't covered by the other specific codes like Director's Dealing (DIRS) or Major Shareholding Notification (MRQ).
2023-03-01 French
Number of voting rights as of February 28, 2023
Share Issue/Capital Change Classification · 95% confidence The document explicitly states it is a 'MONTHLY PUBLICATION OF THE NUMBER OF SHARES COMPOSING THE SHARE CAPITAL AND OF THE TOTAL NUMBER OF VOTING RIGHTS' as required by French commercial code (Article L.233-8 II of the Code de Commerce and Articles 221-1 and 223-16 of the Règlement général of the l'AMF). This type of regular disclosure regarding the total number of shares and voting rights, especially when published monthly, is a specific regulatory filing requirement. It is not a full annual report (10-K), an earnings release (ER), or a dividend announcement (DIV). It most closely aligns with a specific regulatory disclosure that doesn't fit the other defined categories perfectly, but the core content is about the capital structure and voting rights count. Given the options, this is a specific regulatory disclosure. Since there is no specific code for 'Share Capital/Voting Rights Publication', and it is a mandatory regulatory filing, it falls best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory periodic disclosure that isn't covered by the more specific financial or corporate action codes. However, upon re-evaluation against the provided definitions, the content is a direct report of capital structure data, not an announcement *about* a report. Since it details the number of shares and voting rights, it is a fundamental piece of corporate structure information. None of the codes perfectly match 'Share Capital/Voting Rights Publication'. It is not a Director's Dealing (DIRS), Share Issue (SHA), or Transaction in Own Shares (POS). Given the mandatory nature and specific content, RNS (Regulatory Filings) is the most appropriate fallback for a mandatory, non-standard disclosure.
2023-03-01 English
Nicox: Ordinary Shareholder Meeting of February 28, 2023 - Approval of all Resolutions
AGM Information Classification · 99% confidence The document is a press release dated March 1st, 2023, announcing the results of the 'Ordinary Shareholder Meeting of February 28, 2023'. It explicitly states that 'all the resolutions submitted to the Ordinary Shareholder Meeting... have been voted' and approved. This content directly relates to the outcomes of a shareholder meeting. The most appropriate classification among the provided options is AGM-R (AGM Information), as it reports on the results and approvals from the Annual General Meeting. Although it reports the results (which could sometimes overlap with DVA), the context is the formal announcement following the AGM event itself.
2023-03-01 English
Nicox : Assemblée Générale Ordinaire du 28 février 2023 – Approbation des résolutions
AGM Information Classification · 99% confidence The document is titled 'Communiqué de presse' (Press Release) and announces that the resolutions submitted to the 'Assemblée générale ordinaire' (Ordinary General Meeting) held on February 27, 2023, were voted upon and approved. Specifically, it mentions the approval of the transfer of listing to Euronext Growth Paris. This document reports the results of a shareholder vote from a general meeting. According to the definitions, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) covers 'Official results from shareholder votes at any general meeting (AGM or EGM)'. Although it is a press release format, its core content is the declaration of voting results.
2023-03-01 French

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.